Curebase

Exciting news: today we are launching a groundbreaking new product within our unified eClinical Platform. Introducing the Curebase Fax Machine: The Fax Solution Clinical Research Has Been Waiting For! San Francisco, CA — April 1, 2026 — Curebase, the unified eClinical platform built for modern clinical research, today announced the launch of the Curebase Fax Machine, joining the product suite alongside ePRO/eCOA, eConsent, Recruitment, participant engagement tools, and more. We heard the feedback: clinical trials need more innovation. And that is exactly what we are setting out to achieve. The Curebase Fax Machine features include: ✅ GDPR-compliant toner ✅ Thermal paper EDC integration ✅ Real-time fax tracking (please allow 3-5 business days) ✅ AI busy-signal detection ✅ Automatic cover sheet generation "Our customers have been asking for better communication tools," said Storm Stillman, CEO of Curebase. "We already have a full campaign suite for clinical trial participant engagement across landing pages, email, and SMS. Bringing on the Curebase Fax Machine is the natural next step." Find out more 👉 https://lnkd.in/g4i_tfyh #CurebaseFaxMachine #eClinical #AprilFoolsDay

We're pretty sure nobody has done this before. An AI voice agent, approved by two of the largest IRBs in the world, that can consent participants into clinical trials. Her name is Hope. Every eClinical company has an "AI strategy" on their roadmap right now. Most of it is a chatbot on a help article. Getting IRB approval for AI to actually conduct informed consent is a different thing entirely. Curebase already had IRB approval for Hope to prescreen participants. But prescreening is the easy part. Informed consent is where it really matters, and where the bar is much higher. So we went back and got that approved too. Hope conducts the consent conversation by voice. She walks through the consent form, answers questions about the study in real time, checks comprehension along the way, and unlocks the signature only when the participant is ready. If a participant asks something clinical or outside her scope, she escalates to a real person immediately. This isn't for every study. Complex, high-risk trials need a human guiding that conversation. But let's be honest about what consent looks like for most participants today: you get handed a document in a waiting room and left to read it yourself. The industry spent 20 years digitizing paper consent forms and called it innovation. Hope actually talks to participants. This is what happens when you build a product, not a feature. Most eClinical platforms are assembled through acquisitions. Consent from one company, EDC from another, ePRO from a third. That makes something like Hope a lot harder to pull off. Hope exists because we built the entire consent workflow from scratch. The AI isn't bolted on. It's native to how the system works. Huge shoutout to Sarah Rife who drove this across both IRBs. More to come. #ClinicalTrials #AIinHealthcare #eConsent

Curebase is heading to Boston next week. We'll be at the Fortrea Innovation and Technology Summit on April 7-8, and we'd love to connect. VP of Operations & Strategy Brad Stefanovic and VP of Digital Enrollment Paul Donnelly will both be there. Reach out to talk eClinical technology, patient recruitment, or what a unified platform actually looks like in practice. See you in Boston. 👋 #eClinical #AIinClinicalTrials #ePRO #eConsent #ElectronicDataManagement #PatientRecruitment

eClinical tech should be easy to use. Period. When the UX is good in clinical trial technology, it means real downstream effects on study outcomes like: 👉 Stronger engagement = better data quality 👉 Easier to use platforms reduce participant dropout Yet eClinical tech ease of use is rarely showcased up front. We want to change that. We're starting by putting our platform front and center on our website. Head to curebase.ai to see what it's like to use Curebase for yourself (** no sign up or demo call required**). 👀

Be honest: have you pasted trial info into ChatGPT lately? Then you need to answer this: where did that data go and and who can see it? This article will change how you think about “just running a quick prompt." And it will give you practical questions to ask your vendors. c/o Storm Stillman's talk during #SCOPE2026

Thanks SOS Save Our Sites for featuring us in the Save Our Sites Magazine. They captured the "why" behind Sitebase perfectly; we couldn’t have written it better ourselves. Check it out below and catch us at #SOS2026 later this week!

Meet the team next at SOS Save Our Sites Conference! Stop by Booth #4 for a sneak peek of Sitebase: the modern eClinical platform, free for sites. 👇

Catch us live on Monday at 12 PM EST for the SOS Save Our Sites roundtable! Our CEO Storm Stillman is joining the SOS team to share Curebase's mission and the vision behind the launch of our comprehensive site platform Sitebase: free modern software for sites. Tune in, we'll chat about all things clinical research technology and why sites should never have to choose between top tier tech and their bottom line. Listen in here: https://lnkd.in/eis95hfi #ClinicalResearch #SOSConference #SOS2026 #eClinical

We're ready to kick off day 2 at OCT West! Yesterday was full of great conversations with clinical operations teams navigating challenges around data and technology, and we loved showing them how the expanded Curebase platform tackles exactly that. Unified platform, new recruitment tech, real-time eCOA monitoring with AI, and more. Come find the team today at Booth #6! #OCTWestCoast #OCTWest #ClinicalTrials #ClinicalResearch #eClinical #Curebase

What happens to your study data when you use AI? Our CEO Storm Stillman spoke about this at #SCOPESummit last week and is sharing more about AI data security in clinical research. Read his article on the topic here: https://lnkd.in/eFUqvKyA